News

Filter

Current filters:

GenentechResearch

1 to 9 of 35 results

23andMe and Genentech in deal to analyze genomic data for Parkinson's disease

06-01-2015

23andMe, the leading personal genetics company, and Genentech, a subsidiary of Swiss pharma giant Roche,…

23andMeBiotechnologyGenentechNeurologicalResearchRoche

Phylogica inks $142 million license deal with Genentech

Phylogica inks $142 million license deal with Genentech

22-12-2014

Australian drug discovery firm Phylogica has extended its collaboration with Genentech, the biotech subsidiary…

Antibiotics and Infectious diseasesAustraliaBiotechnologyGenentechLicensingPhylogicaResearchRoche

Eylea beats Avastin and Lucentis for visual acuity in DME patients

Eylea beats Avastin and Lucentis for visual acuity in DME patients

19-10-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer saw their shares leap 8.5% to…

AvastinBayerBiotechnologyEyleaGenentechLucentisNovartisOphthalmicsRegeneron PharmaceuticalsResearchRoche

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

03-03-2014

An independent data monitoring committee has recommended that Swiss drug major Roche’s Phase III METLung…

BiotechnologyGenentechonartuzumabOncologyResearchRoche

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Novartis presents strong new Ph III results with omalizumab in CSU

Novartis presents strong new Ph III results with omalizumab in CSU

05-10-2013

Novartis has presented new results from the Phase III ASTERIA I study showing omalizumab was effective…

DermatologicalsGenentechNovartisOmalizumabPharmaceuticalResearchXolair

Immunocore and Genentech collaborate to develop ImmTACs for multiple cancer targets

01-07-2013

Immunocore, an Oxford, UK-based biotechnology company developing novel biological drugs known as ImmTACs…

BiotechnologyGenentechLicensingOncologyResearchRoche

1 to 9 of 35 results

COMPANY SPOTLIGHT

Menarini

Back to top